Effect of ketanserin, a new blocking agent of the 5-HT2 receptor, on airway responsiveness in asthma.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 2180341.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Most of the antihypertensive drugs have a liability for adverse effects in asthma. Since there are few available data on the effect of ketanserin, a new antihypertensive drug which is a type-2 serotonin receptor antagonist, on human respiratory function, we have tested whether this drug can modify bronchial hyperresponsiveness to methacholine in asthmatic patients. The protective effect of intravenous ketanserin (0.14 mg/kg) was small, but significant.
Medical subject headings
- Asthma
- Bronchi
- Ketanserin
- Methacholine Compounds